文献速递腹部CT

双层双能CT评估乏血供肝转移瘤:关闭k-edge对图像质量和病灶可检测性的影响

Dual-layer dual-energy computed tomography for the assessment of hypovascular hepatic metastases: impact of closing k-edge on image quality and lesion detectability.
PubMed 文献 · Eur Radiol · 2018-10-30

研究纳入81例乏血供肝转移瘤患者行门静脉期腹部双层双能CT,重建多能图像(PEI)及40-200 keV虚拟单能图像(VMI),测量噪声、瘤肝对比度及对比噪声比(CNR),并由两名放射科医师主观评估图像质量;结果显示VMI40-70客观与主观图像质量均优于PEI,VMI40对病灶(尤其直径<10 mm者)的可检测性显著优于PEI。

要点

  • VMI40-70客观与主观图像质量均优于PEI,诊断信心最高为VMI40,其次VMI50-70。
  • VMI40-200图像噪声均低于PEI(p<0.01),VMI40-70的CNR高于PEI(p<0.01)。
  • VMI40病灶可检测性显著优于PEI,尤其对直径<10 mm病灶(p<0.01,kappa≥0.6)。

核心结论

  • VMI40-70在评估乏血供肝转移瘤时提供更好的主观与客观图像质量,VMI40较常规PEI提高病灶可检测性。

研究设计与样本

  • 纳入81例乏血供肝转移瘤患者行门静脉期腹部双层双能CT(DLCT),重建PEI及40-200 keV(间隔10 keV)VMI;测量肝实质与转移结节(n=288)的图像噪声、瘤肝对比度及CNR;两名放射科医师独立以5分法主观评估PEI与最佳VMI的图像质量;对38例每例最多10个直径<25 mm转移灶(153个病灶)盲法比较PEI与最佳能量VMI的病灶可检测性与清晰度。

关键影像表现/征象

  • VMI40-200图像噪声持续低于PEI(p<0.01)。
  • 瘤肝对比度与CNR随能量降低而升高,VMI40-70的CNR高于PEI(p<0.01)。
  • 诊断信心主观评分最高为VMI40,其次为VMI50-70,均显著优于PEI(p<0.01,kappa=0.75)。
  • VMI40病灶可检测性显著优于PEI,尤其对直径<10 mm病灶(p<0.01,kappa≥0.6)。

诊断标准与关键数值

  • 图像质量主观评估采用5分法,评估图像对比度、图像噪声和诊断信心。
  • VMI40-200图像噪声均低于PEI(p<0.01);VMI40-70的CNR高于PEI(p<0.01)。
  • 诊断信心评分VMI40最高,VMI50-70次之,均显著优于PEI(p<0.01,kappa=0.75)。
  • VMI40病灶可检测性显著优于PEI,尤其直径<10 mm病灶(p<0.01,kappa≥0.6)。

临床应用与阅片要点

  • 门静脉期DLCT评估乏血供肝转移瘤时,VMI40-70可提供优于PEI的主观与客观图像质量。
  • VMI40在不过度增加图像噪声的前提下最大化瘤肝对比度与CNR。
  • VMI40较PEI提高病灶可检测性,尤其对直径<10 mm的小转移结节。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the image quality of virtual-monoenergetic-imaging (VMI) from dual-layer dual-energy CT (DLCT) for the assessment of hypovascular liver metastases and its effect on lesion detectability.

METHODS: Eighty-one patients with hypovascular-liver-metastases undergoing portal-venous-phase abdominal DLCT were included. Polyenergetic-images (PEI) and VMI at 40-200 keV (VMI40-200, 10-keV interval) were reconstructed. Image noise, tumor-to-liver contrast, and contrast-to-noise ratio (CNR) of hepatic parenchyma and metastatic nodules (n = 288) were measured to determine the optimal monoenergetic levels. Two radiologists independently and subjectively assessed the image quality (image contrast, image noise, and diagnostic confidence) of PEI and optimal VMI on 5-point scales to determine the best energy. For 38 patients having up to 10 metastases each with diameters < 25 mm (153 lesions), we compared blindly assessed lesion detectability and conspicuity between PEI and VMI at the best energy.

RESULTS: Image noise of VMI40-200 was consistently lower than that of PEI (p < 0.01). Tumor-to-liver contrast and CNR increased as the energy decreased with CNR at VMI40-70 being higher than that observed on PEI (p < 0.01). The highest subjective score for diagnostic confidence was assigned at VMI40 followed by VMI50-70, all of which were significantly better than that of PEI (p < 0.01, kappa = 0.75). Lesion detectability at VMI40 was significantly superior to PEI, especially for lesions with diameters of < 10 mm (p < 0.01, kappa ≥ 0.6).

CONCLUSIONS: VMI40-70 provided a better subjective and objective image quality for the evaluation of hypovascular liver metastases, and the lesion detectability was improved with use of VMI40 compared with conventional PEI.

KEY POINTS: • DLCT-VMI at 40-70 keV provides a superior subjective and objective image quality compared with conventional PEI for the assessment of hypovascular hepatic metastases during portal venous phase. • Tumor-to-liver contrast and CNR of hypovascular hepatic metastases was maximized at 40 keV without a relevant increase in the image noise. • VMI at 40 keV yields a superior lesion detectability, especially for small (< 1 cm) metastatic nodules compared with conventional PEI.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Nagayama Y, Iyama A, Oda S, et al. Dual-layer dual-energy computed tomography for the assessment of hypovascular hepatic metastases: impact of closing k-edge on image quality and lesion detectability. Eur Radiol. 2018. PMID: 30377793. doi:10.1007/s00330-018-5789-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。